Stage II Renal Cell Cancer Clinical Trial
Official title:
Prospective Study of Interstitial Brachytherapy for Unresectable/Unablatable T1b/T2a Renal Masses
This phase I/II trial investigates the side effects of interstitial brachytherapy and to see how well it works in limiting the growth of large kidney cancer masses in patients with kidney cancer that have refused or are unable to undergo surgery or ablation (unresectable/unablatable). Brachytherapy, also known as internal radiation therapy, temporarily introduces a radiation source into or near the tumor to eradicate the tumor cells. Giving brachytherapy may potentially reduce the size of the kidney cancer mass that would otherwise not be amenable to surgical management and translate into lower risk of spread.
PRIMARY OBJECTIVES: I. To determine the safety and feasibility of renal interstitial radiation therapy (interstitial brachytherapy). (Safety Lead-In) II. To evaluate local control of renal interstitial brachytherapy. (Expansion Phase) SECONDARY OBJECTIVES: I. To evaluate treatment response of the primary tumor. II. To evaluate 12 month distant progression free survival. III. To evaluate the 12 month volumetric growth of the primary tumor mass. IV. To determine biomarkers predicting response and resistance to radiation treatment. OUTLINE: Patients undergo interstitial brachytherapy for 1-2 fractions in the absence of disease progression or unacceptable toxicity. Patients who undergo 2 fractions may receive both fractions in the same day or on 2 separate days over 2 weeks. After completion of study treatment, patients are followed up every 3 months for at least 3 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02664883 -
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
|
||
| Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
| Completed |
NCT01243359 -
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01281488 -
Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors
|
Phase 1 | |
| Terminated |
NCT02170389 -
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
|
N/A | |
| Withdrawn |
NCT01769885 -
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
|
N/A | |
| Completed |
NCT01158521 -
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
|
Phase 2 | |
| Completed |
NCT00335556 -
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT06447103 -
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06432036 -
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
|
Phase 1/Phase 2 | |
| Terminated |
NCT02767921 -
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02526511 -
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
|
N/A |